Dr. Jacobson on the Next Steps With Axi-Cel in R/R Indolent Non-Hodgkin Lymphoma

Video

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Caron Jacobson, MD, medical director of the Immune Effector Cell Therapy Program; a physician at Dana-Farber Cancer Institute; and an assistant professor of medicine at Harvard Medical School, discusses the next steps with axicabtagene ciloleucel (axi-cel; Yescarta) in relapsed/refractory indolent non-Hodgkin lymphoma.

At the 2020 ASCO Virtual Scientific Program, findings from the phase 2 ZUMA-5 study demonstrated a 95% overall response rate with a complete response rate of 81% in patients with relapsed/refractory follicular lymphoma. Additionally, clinical benefit was noted with the CAR T-cell therapy in patients with marginal zone lymphoma (MZL).

The data remain immature, and patients are still enrolling to the MZL cohort, says Jacobson. In the follicular lymphoma cohort, a planned 12-month analysis may shed light on the durability of these responses.

ZUMA-5 is designed to be a pivotal study for axi-cel to receive an expanded indication from the FDA in lymphoma, explains Jacobson.

Moreover, if the durability and safety profile of the agent continue to elicit favorable data, axi-cel or other CAR T-cell therapies may be evaluated in earlier lines of treatment for high-risk patients, including those who progress following initial chemoimmunotherapy, concludes Jacobson.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD